Follicle Stimulating Hormone (FSH)
Follicle-stimulating hormone (FSH) is a glycoprotein secreted by the anterior pituitary gland. The structure for FSH is similar to LH, TSH, and hCG as the alpha portion of the molecules are identical. The beta portion is what differs in all. Production of the FSH molecule is regulated by hypothalamic gonadotropin releasing hormone (GnRH) and feedback from gonadal steroid hormones. FSH and LH belong to the gonadotropin family, and synergistically regulate and stimulate the growth and function of male and female sex organs. In the female, FSH stimulates follicular growth, prepares ovarian follicles for luteinizing hormone (LH) activity, and enhances the LH-induced release of estrogen. Testing for both FSH and LH are useful in the diagnosis, management, and treatment of infertility in both genders. After menopause, decreased ovarian estradiol secretion results in increased FSH and LH levels. Because of this, increased FSH levels are associated with menopause. Increased levels can also be associated with primary ovarian hypofunction in females, and primary hypogonadism in males. Increased levels during the childbearing years are considered an abnormal disease state. Abnormal FSH levels with corresponding increased or decreased levels of LH, estrogens, progesterone, and testosterone are associated with a number of pathological conditions. In the male, FSH stimulates seminiferous tubule and testicular growth and is involved in the early stages of spermatogenesis. Primary testicular failure results in increased FSH and LH levels. Decreased FSH levels are associated with primary ovarian hyperfunction in females, and primary hypergonadism in males and/or are indicative of pituitary or hypothalamic dysfunction. Normal or decreased FSH levels are associated with polycystic ovary disease in females.
- Diagnosis of male and female hypogonadism or gonadal insufficiency
- Pituitary function test to distinguish primary gonadal failure from secondary (hypothalamic/pituitary) causes of menstrual disturbance and amenorrhea
- To define menstrual cycle phases in infertility evaluation of women and men
- Diagnosis, management and treatment of infertility in women and men
Increased in:
- Primary gonadal failure
- Ovarian or testicular agenesis
- Turner's Syndrome
- Castration and Anorchia (Testicular Agenesis in male)
- Postmenopause
- Klinefelter syndrome
Decreased in:
- Hypothalamic disorders
- Adrenal or Ovarian Neoplasm
- Polycystic Ovarian Disease
- Pituitary disorders
- Pregnancy
- Some drugs such as corticosteroids, oral contraceptives, estrogens, testosterones
Unit: mU/mL or U/L
| Prepubertal Child | |
| Group | mU/mL or U/L |
| 2–11 mo Male | 0.19–11.3 |
| 2–11 mo Female | 0.10–11.3 |
| 1–10 yr Male | 0.3–4.6 |
| 1–10 yr Female | 0.68–6.7 |
| Puberty (by Tanner Stage) | |
| Stage / Sex | mU/mL or U/L |
| Stage 1–2 Male | 0.30–4.6 |
| Stage 1–2 Female | 0.68–6.7 |
| Stage 3–4 Male | 1.24–15.4 |
| Stage 3–4 Female | 1.0–7.4 |
| Stage 5 Male | 1.53–6.8 |
| Stage 5 Female | 1.0–9.2 |
| Adults | |
| Group | mU/mL or U/L |
| Adult Male | 1.42–15.4 |
| Female, Follicular phase | 1.37–9.9 |
| Female, Ovulatory peak | 6.17–17.2 |
| Female, Luteal phase | 1.09–9.2 |
| Female, Postmenopausal | 19.3–100.6 |
Immunochemilumonmetric assay, Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA).
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Fertil Steril. 2012 Jan;97(1):231-4. [PMID: 22118994]
- Ann Clin Biochem. 1988 Nov;25 (Pt 6):601-9. [PMID: 3151047]
- JAMA. 2003;289:895. [PMID: 12588275]
- Clin Chem. 1989 Apr;35(4):620-9. [PMID: 2522836]
- Am J Med. 2005;118 (Suppl 12B):8. [PMID: 16414322]
- BJOG. 2006;113:1472. [PMID: 17176280]